Research
Hormonal
SGLT2 inhibitors are recommended for type 2 diabetes patients with heart failure with reduced ejection fraction (HFrEF) to reduce hospitalization for heart failure, MACE, and cardiovascular death.
If you have type 2 diabetes and heart failure, especially with reduced ejection fraction, ask your doctor about SGLT2 inhibitors. These drugs are proven to reduce hospitalizations for heart failure and cardiovascular death, offering protection beyond blood sugar control.
WeakSupportsHIGH confidence
SGLT2 inhibitors are recommended in patients with type 2 diabetes and HF, particularly those with HFrEF, to reduce hHF, MACE, and CV death.
Why this rating
Based on DAPA-HF and other CVOTs.
Source
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al. · Diabetes Care · 2019
DOI 10.2337/dci19-0066
clinical_guidelineCited 1,186×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In high-risk type 2 diabetes patients, GLP-1 receptor agonists and SGLT2 inhibitors reduce major adverse cardiovascular events (MACE), heart failure hospitalization, and chronic kidney disease progression independently of baseline HbA1c levels.Weak
- SGLT2 inhibitors are recommended for type 2 diabetes patients with chronic kidney disease (CKD) to prevent CKD progression, heart failure hospitalization, MACE, and cardiovascular death.Weak
- GLP-1 receptor agonists are recommended for type 2 diabetes patients with established atherosclerotic cardiovascular disease (ASCVD) to reduce MACE, with the strongest evidence for dulaglutide.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →